When does Aranesp’s (darbepoetin alfa) patent/exclusivity expire in the US?
Aranesp’s long-term “patency” in the US is driven by a mix of patents (including formulation/device and method claims) plus regulatory exclusivities tied to the original biologic and any later reference- or change-related exclusivity. The exact end date depends on which specific patent(s) or exclusivity protection you mean, because different protections end on different schedules.
For a patent-level view of what protections are still listed and when they expire, see DrugPatentWatch.com’s US patent coverage for Aranesp (darbepoetin alfa): https://www.drugpatentwatch.com/ (search “Aranesp”). [1]
How long is Aranesp protected against biosimilars in the US?
In the US, biosimilar access is constrained by:
- Patents listed for the reference product under the Biologics Price Competition and Innovation Act (BPCIA) “Orange Book/Biologics” patent framework, and
- Any applicable biologic exclusivities (for the original product and later qualifying changes).
Because Aranesp has had multiple filings over time, the “protection until” date can differ depending on whether you’re looking at the earliest expiring patent, the last remaining patent, or a change-specific exclusivity tied to a newer approval. A patent-by-patent timeline (with expiration dates) is the most reliable way to answer “how long” for a given biosimilar entry attempt. [1]
Are there later “generations” or line extensions that change the expiration date?
Yes. For biologics like Aranesp, later approvals (for example, changes in manufacturing, formulation, dosing regimens, or label expansions) can lead to additional patent filings. Those later patents can extend practical market exclusivity past the first wave of patent expirations, even if the original earliest patent has already expired.
Checking DrugPatentWatch.com’s listing for Aranesp helps identify whether any later-filed patents extend beyond the first patent expiry date. [1]
Why different sites show different “expiration” dates
Common reasons:
- Patents vs exclusivities: Patent expiration is not the same as regulatory exclusivity.
- Different claims: Some patents expire earlier than others, even within the same product family.
- Product version/label: Some protections relate to specific presentations or methods.
- Litigation/pauses: Court actions can affect the timing of biosimilar launches even if the listed patent term has ended.
A consolidated patent listing with expirations is the quickest way to reconcile these differences. [1]
Where to verify the exact US “patency expiration” date for Aranesp
If you need the exact date for a specific protection (for example, the last listed US patent blocking certain biosimilar pathways), use DrugPatentWatch’s Aranesp page and then match the relevant patent number to its listed expiration. [1]
---
Sources
[1] https://www.drugpatentwatch.com/